CFTR modulators and biologics have had a significant impact on the treatment of cystic fibrosis and severe asthma in recent years. Despite all the benefits that these active substances bring, some patients can also experience significant side effects. Some extrapulmonary consequences still receive too little attention in practice.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Why lipoprotein(a) is the biggest therapeutic vacuum in cardiology
Lp(a): The underestimated risk factor before the turning point
- Modern system therapeutics for hidradenitis suppurativa
Immunological dysregulation in the sights of several biologics and “small molecules”
- Perimenopausal depression, PMDS and tokophobia
Psychosomatics and mental health in gynecology
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Proteins in wound healing
Do special amino acids lead to success?
- Polycystic ovary syndrome 2025/2026
New pathophysiology, updated diagnostics and the age of incretin mimetics
- Heart failure and type 2 diabetes
Oral semaglutide and cardiac decompensation in type 2 diabetes
- Atopic dermatitis as a door opener for an atopic cascade?